Advaxis to Present at Upcoming Investor Conferences

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Advaxis to Present at Upcoming Investor Conferences

PRINCETON, N.J., Sept. 8, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc.   (Nasdaq: ADXS ), a clinical-stage biotechnology company developing cancer immunotherapies, announced that Daniel J. O'Connor, Chief Executive Officer of Advaxis, will be presenting a company update at the upcoming investor conferences:

  • Rodman & Renshaw 16 th Annual Global Investment Conference, New York, NY. Presentation: Tuesday, September 9, 2014.
     
  • Aegis Capital Corporation 2014 Healthcare and Technology Conference, Las Vegas, NV. Presentation: Thursday, September 11, 2014.

The above presentations will be webcast. Links to the live and archived webcasts will be available from the investor relations section of the company's website at http://ir.advaxis.com/ir-calendar .

About Advaxis, Inc.

Advaxis is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform intended to redirect the immune system to kill cancer. The Advaxis Lm -LLO technology, using bioengineered live attenuated Listeria monocytogenes bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and MSDCs, that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis's lead immunotherapy, ADXS-HPV, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The FDA has granted Advaxis orphan drug designation for each of these three indications. The Company plans to initiate a registrational clinical program for cervical cancer in 2014 and has established licensing partners in India and Asia for commercialization in those regions. Advaxis is planning to evaluate the combination of ADXS-HPV with an anti-PD-L1 immune checkpoint inhibitor in HPV-associated cancers.

Advaxis's second immunotherapy candidate in clinical testing will be ADXS-PSA, which is being developed to address prostate cancer. Advaxis is planning to file an IND with the FDA and initiate a Phase 1/2 clinical study with ADXS-PSA in combination with a PD-1 checkpoint inhibitor. Advaxis is also developing ADXS-cHER2, to target the Her2 receptor overexpressing cancers. Her2 is overexpressed in certain solid-tumor cancers, including pediatric bone cancer (or osteosarcoma), breast cancer, esophageal, and gastric cancer. Advaxis is developing ADXS-cHER2 for both human and animal-health, and has seen promising results in canine osteosarcoma, which is considered a model for human osteosarcoma. Advaxis is pursuing a clinical program in pediatric osteosarcoma and has licensed ADXS-cHER2 and three other immunotherapy constructs to a major animal-health company. Advaxis is planning to file an IND for ADXS-cHER2 in Her2 overexpressing cancers.

For more information please visit www.advaxis.com or connect with us on

Forward-Looking Statements

This news release contains forward-looking statements, including, but not limited to: statements regarding Advaxis's ability to develop the next generation of cancer immunotherapies; the safety and efficacy of Advaxis's proprietary immunotherapy, ADXS HPV; whether Advaxis immunotherapies can redirect the powerful immune response all human beings have to the bacterium to cancers. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis's SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2013, which is available at http://www.sec.gov . Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

Advaxis Contact: Lisa Caperelli Senior Director of Investor Relations and Corporate Communications Advaxis, Inc. 215.206.1822 Media Contact: Tiberend Strategic Advisors, Inc. Amy S. Wheeler 646.362.5750

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AR Cards in Casino Gaming: A High-Stakes Revolution

Updated Category News Views 13

A New Breed of Casino Experience Walk into a casino today, and you might just enter a whole new reality. No, this isn’t a cheesy magician’s trick or a glitzy PR stunt—this is the real deal brought to you by augmented reality (AR) trading cards. Imagine the slots you love wrapped in a sci-fi movie where characters leap out, tap you on the shoulder, and call you by...

Continue Reading
Nevada Expands Rural Youth Mental Health Access

Updated Category News Views 148

Nevada's Rural Mental Health Crisis When you're navigating the barren stretches of rural Nevada, the scenic views can be breathtaking. But for many families, finding basic services like mental health care is as challenging as striking water in the desert. Cartwheel Care has taken the bull by the horns with their latest initiative to bridge this glaring gap. Partnering...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 221

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 199

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
Lululemon Faces Class Action over Alleged Missteps

Updated Category News Views 39

Trouble Brewing for Lululemon Y'ever get that gut feeling when something doesn't smell right? Well, Lululemon Athletica (NASDAQ: LULU) investors are probably feeling that now. A class action's kicking up dust over what some are saying was a downright bumpy ride. The brainiacs at Robbins LLP urge those who've lost bucks riding the LULU train to step forward ahead of the...

Continue Reading
Exploring Creation: A Fresh Look at Genesis

Updated Category News Views 67

Opening Up Genesis in a New Light Hey, if you’re like most folks, you’ve probably heard Genesis framed as the battleground for science versus religion debates, right? Enter into this mix a fresh take with Robert E. Franzen’s new book, The Narration of Creation. This book asks you to overlook those grand philosophical fights and instead focus on the narrative itself....

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 278

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 106

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 53

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
Trades Workforce Shortage Costs Wallop U.S. Economy

Updated Category News Views 83

The Forgotten Backbone of America Don't sleep on this: America's got itself a trade worker crisis, and it's not just a numerical hiccup. We’re down nearly 1.9 million skilled trades workers, and that's a gut punch to the economy—a hefty $1.2 billion a day in GDP loss. These are the folks who keep the wheels greased, the lights on, and the goods flowing. Without them,...

Continue Reading

Top 5 Most Recently Viewed Articles

US Agriculture Partners with CeresAI for Enhanced Farming Insights

Updated Category News Views 168

US Agriculture and CeresAI: A Groundbreaking Collaboration In an innovative move, US Agriculture, LLC has teamed up with CeresAI to transform farmland monitoring through advanced technology. This partnership aims to leverage artificial intelligence for improved performance in agricultural investments by optimizing farmland management and reducing costs associated with...

Continue Reading
Infosys Launches New Zurich Office to Drive AI Innovations

Updated Category News Views 175

Infosys Expands Its Zurich Office for Enhanced Client Collaboration Infosys, a global trailblazer in digital services and consulting, has inaugurated its new office in Zurich, Switzerland, marking a pivotal moment in its 25-year journey within the Swiss market. With this move, Infosys not only relocates its Swiss headquarters to The Circle at Zurich Airport but also...

Continue Reading
SierraConstellation Partners Celebrates Significant Award Wins

Updated Category News Views 117

A Major Milestone for SierraConstellation Partners SierraConstellation Partners (“SCP”), a foremost interim management and advisory firm, has received several prestigious awards for its outstanding work in business restructuring. The Global M&A Network has recognized SCP's exemplary handling of both the sale of Vyera Pharmaceuticals' assets and the reorganization of...

Continue Reading
Kaltura's AI Innovations Recognized in Market Guide

Updated Category News Views 179

Kaltura's Recognition in the Industry Kaltura, a leader in AI Video Experience Cloud technology, has recently been acknowledged as a Representative Vendor in the Gartner Market Guide for Video Platform Services. This recognition is a testament to Kaltura's forward-thinking approach and its commitment to enhancing enterprise video solutions. The Importance of Video...

Continue Reading
Liberty Gold’s Annual Meeting Outcomes: New Leadership and Directions

Updated Category News Views 288

Liberty Gold Announces Annual General Meeting Results Vancouver, British Columbia – Liberty Gold Corp. (TSX: LGD; OTCQX: LGDTF) has shared the outcomes of its recent Annual General Meeting (AGM) where shareholders participated in crucial decisions shaping the future leadership of the company. The AGM marked a significant moment for Liberty Gold as it transitions into a...

Continue Reading